MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 https://www.businesswire.com/news/h...-with-Three-Phase-3-Readouts-Expected-in-2026